C urrent treatment guidelines for atrial fibrillation (AF) base decisions on the triad of prevention of symptoms and protection from stroke and tachycardia-mediated cardiomyopathy. Conceptually, all of these objectives could be satisfied by either timely cardioversion and subsequent rhythm control, or the admittedly easier (for the patient and the physician) rate control strategy. We feel strongly that pharmacological or electrical cardioversion is worth the effort and should in fact usher in a new paradigm for AF disease management, rather than the passive and defeatist approach currently in place.
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AF is the most frequent arrhythmia in clinical practice and a major cause of morbidity and mortality. 1 More than 100 years after Sir James Mackenzie first described a pulse irregularity associated with disappearance of the "a" wave from the jugular pulse and paralysis of the atria, 2 the pathophysiology of AF remains incompletely understood. However, over the last half century it was realized that electrical, contractile, and structural remodeling are fundamental contributors to the disease process of AF, potentially allowing improved and more specific therapies. Traditional therapy for AF consists of empirically tested ion channel blockers, offered without a real understanding of the pathophysiologic basis of the disease. It is therefore not surprising that pharmacological therapies for AF are neither as effective nor as safe as we would like. In major clinical trails, which have traditionally based success on absence of symptoms alone, antiarrhythmic drugs (AADs) prevent recurrent AF in 50% to 65% over short-term follow-up. It is largely due to frustration from current AADs that studies comparing rate control with rhythm control were conducted. Although the debate of rhythm versus rate control continues, it is important to realize that with either therapy, mortality trends in patients with AF remained unabated. In a longitudinal cohort study of patients with newly diagnosed AF, modern treatment provided no change in the overall age and gender-adjusted mortality over a 21-year period, even after adjustment for various comorbidities. 3 This observation is particularly alarming in the face of the rapidly growing prevalence of AF in the United States. Our goal, therefore, should not be replacing one failed therapy with another, but finding new therapies that improve the natural history and survival of patients with AF.
AF is commonly associated with other cardiovascular diseases such as coronary artery disease or heart failure, but the causative relationship between these conditions has not been fully determined. Although this association can be explained by the presence of common risk factors such as age, hypertension, diabetes mellitus, obesity, and valvular and nonvalvular structural heart disease, AF confers a poorer prognosis, even after adjusting for these risk factors. 4 -10 Thus, at a time when better therapies for coronary artery disease and heart failure result in improved longevity, the independent prognostic role of AF could be much higher. This observation also highlights the contrast between the progress we made in understanding and treating coronary disease and heart failure as opposed to AF. Up until a decade ago, therapy for heart failure largely consisted of pharmacological inotropic support, a therapy that made complete physiological sense in the failing heart with a reduced cardiac output. Similar to the therapy of AF with currently available AADs, treatment of heart failure with digoxin resulted in symptomatic improvement without conferring a survival benefit. 11 Not until groundbreaking research established the fundamental role of neuroadrenegic activation in heart failure did disease-modifying therapies became available. In a similar manner, better understanding of mechanisms underlying the development and progression of AF is crucial for advancement in therapeutic options. Elucidation of the mechanisms and pathways involved in remodeling the left atria may set the stage for a new era in the therapy of AF. Selective interference in the remodeling process may halt the progression of AF or even prevent its appearance in high-risk groups of patients.
Left Atrial Remodeling in AF
Remodeling is an adaptive regulatory process of cardiac myocytes that occurs over time in order to maintain homeostasis against external stresses. 12 Adaptive remodeling may occur at the ionic, genomic, cellular, and extracellular levels. [13] [14] [15] If the stressor is removed early enough, this process can be reversible. However, if left untreated, irreversible cellular and extracellular changes such as apoptosis, necrosis, and fibrosis can occur as early as after 1 month. Moreover, changes in gene expression, hormone regulation, distribution of cellular ionic channels, and recalibration of energy production and expenditure all synergize to promote a self-perpetuating cascade of reactions, which leads to irreversible and deleterious maladaptive remodeling of the left atrium.
Electrical Remodeling
With the onset of AF, electrical remodeling of the left atria begins, as does the inexorable progression from paroxysmal to persistent AF. In a landmark study, Wijffels et al 16 were the first to demonstrate in an experimental animal model that AF provokes structural and functional alterations that favor perpetuation of the arrhythmia. The repetitive induction of AF in goat hearts using rapid pacing induced longer-lasting episodes of AF, higher vulnerability for induction, and lower likelihood of spontaneous conversion to sinus rhythm. This phenomenon can be partially explained by the following model: At rapid atrial rates, inward calcium current significantly increases myocyte calcium load. Because high intracellular calcium concentrations can be toxic, adaptive mechanisms rapidly reduce the load to protect the cell. Early in the remodeling process, the membrane channel responsible for calcium entry becomes less active and is eventually downregulated. [17] [18] These changes ultimately reduce the inward calcium current, which shortens action potential duration. Hence adaptive mechanisms that respond to intracellular calcium loads ultimately shorten the atrial refractory period, promoting functional re-entry and perpetuation of AF. 19
Structural Remodeling
Structural remodeling in AF is characterized by atrial dilatation and interstitial fibrosis. 20 In recent years, atrial fibrosis has been recognized as the hallmark of arrhythmogenic structural remodeling. 15 Tissue fibrosis results from an accumulation of fibrillar collagen deposits, occurring most commonly as a reparative process to replace degenerating myocardial parenchyma with concomitant reactive fibrosis. 20 -22 Although atrial fibrosis occurs as a convergent pathological end point in a variety of cardiovascular conditions, increased collagen deposition has been documented also in patients with lone AF, highlighting the critical association between atrial fibrosis and AF. 23 In the dog model, atrial fibrosis causes localized regions of conduction slowing and increased conduction heterogeneity, providing the substrate for AF. 15 Although the precise mechanism of atrial fibrosis is not entirely clear, data from animal models implicate angiotensin-converting enzyme and angiotensin II as upstream regulators of profibrotic molecules such as transforming growth factor ␤1. 24 -26 These findings may have therapeutic implications, as attenuation and reversal of atrial fibrosis with angiotensin-converting enzyme-I, angiotensin II type 1 receptor blockers seems to inhibit fibrosis and result in lower susceptibility to develop AF in animal models. 26 -31 
Prevention of Left Atrial Fibrosis
Although remodeling of the left atrium may not necessarily be the underlying cause of AF, there is substantial evidence to support its fundamental role in the cascade of events leading to the development of persistent AF. Because remodeling is a dynamic process with a wide range of pathophysiologic changes occurring in a stepwise manner, interventions to remove the inciting stimuli can slow, arrest, or even reverse this process. However, if left untreated, cellular and structural changes may become irreversible, and the arrhythmia perpetuates. Data from studies in humans is limited to retrospective analyses of clinical trials with angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers, and 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. These studies have demonstrated a reduction in the risk to develop AF in patients at the highest risk of structural remodeling. 32 Several ongoing prospective studies promise to clarify the effects of these drugs on atrial remodeling and the propensity to develop AF. Although these observations are early, and our ability to interrupt the pathophysiologic processes incomplete, we feel that they warrant fresh evaluation of our working paradigm. Treatment of AF should start with prevention of atrial remodeling. This can be achieved with treatment of hypertension, sleep apnea, obesity, or hyperthyroidism. Once AF occurs, early restoration of sinus rhythm can disrupt progression of atrial remodeling, whereas the addition of disease-modifying agents may possibly lead to reversal of this process.
Risk of Stroke
AF is the single most important cause of ischemic stroke. The rate of ischemic stroke among patients with nonrheumatic AF averages 5% per year, which is between 2 and 7 times that of individuals without AF. [33] [34] [35] [36] [37] [38] Moreover, the risk of stroke increases with age; in the Framingham Heart Study, the annual risk of stroke attributable to AF increased from 1.5% in participants aged 50 to 59 years to 23.5% for those aged 80 to 89 years. 34 Multiple studies have demonstrated that adjusted-dose warfarin reduces this risk by approximately 60%, at the cost of a small increase in serious bleeding, including intracranial hemorrhage. 39 -42 Although warfarin therapy is effective, the lifetime residual risk of stroke and complications of anticoagulant therapy may still be substantial.
This fact exposes the important logical inconsistency of judging therapies using the myopic lens of clinical trials. AF is potentially a lifelong disease process, with escalating risk as patients age. Although it could be argued that passive therapies work out acceptably over a 2-to 3-year time frame, it is difficult to justify allowing the inexorable progression of a process that is very likely to cause harm over the course of decades.
Rhythm Versus Rate Control
Timely cardioversion only makes sense in the context of appropriate therapies to maintain sinus rhythm. Randomized trials comparing rhythm and rate control strategies over a short time frame have consistently failed to demonstrate a mortality benefit with rhythm control. [43] [44] [45] [46] Moreover, the recently published Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial showed that an initial strategy of rhythm control was not superior to rate control even in patients with heart failure, in whom the theoretical benefit of rhythm control would seem to be higher. 47 In contrast, the Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) studies, a series of trials assessing the efficacy and safety of dofetilide to treat AF, showed that patients who maintained sinus rhythm, either with or without AADs, had a superior prognosis compared with patients with continued AF. 48 Thus it is possible that actual presence or absence of sinus rhythm itself, rather than treatment strategy, is responsible for outcome. In this regard, analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial according to actual treatment revealed that presence of sinus rhythm was associated with a considerable reduction in the risk of death, consistent with the findings of the DIAMOND study (Figure 1 ). 49 However, because of the retrospective and nonrandomized nature of the analyses, neither the DIAMOND study nor the AFFIRM study can distinguish whether sinus rhythm is an important independent determinant of survival or a marker for other factors associated with increased survival.
The results of these studies, although valuable, are often overinterpreted and applied without consideration of inherent limitations. The problem with a short-term assessment of a lifetime disease process has already been stated. Although it was standard of care at the time, these trials took a casual approach to monitoring for AF recurrence. Epochs of undetected AF expose patients to the risk of AAD treatment without benefit. Most participants were older (65 to 75 years) and relatively asymptomatic, with risk factors for stroke that were often incompletely treated. In contrast, a smaller group of younger patients (age Ͻ40 years) with valvular heart disease and AF showed a significant benefit of rhythm control with respect to reduction of mortality and improvement of functional capacity and quality of life (QOL). 50 One of the main reasons to initiate rhythm control therapy in patients with AF is to control symptoms. Patients with AF exhibit a wide variety of clinical symptoms, ranging from none to disabling symptoms. The most common symptoms include palpitations, dizziness, and chest pain. However, more subtle symptoms such as anxiety and fatigue are common as well and could potentially remain undetected . An "on-treatment" analysis of the AFFIRM study allowed for the inclusion of time-dependent variables, such as the presence or absence of sinus rhythm. 49 Multivariable analysis demonstrated that the presence of sinus rhythm is either an important determinant of survival or a marker for other characteristics associated with survival that were not captured in the model. The positive impact of sinus rhythm is essentially equal and opposite of that of AAD therapy. CAD indicates coronary artery disease; HF, heart failure. Reproduced from Corley et al 49 with permission of the publisher. Copyright © 2004, the American Heart Association. unless specifically addressed. Many patients who have "asymptomatic" AF feel much better after successful cardioversion. Several hemodynamic derangements, including rapid ventricular rates, loss of organized atrial contraction, irregularity of cardiac rhythm, and bradycardia (resulting particularly from sinus pauses when AF episodes terminate) may explain some of the symptoms related to AF. Although the true percentage of symptomatic patients with AF is unknown, the impact of atrial fibrillation of health-related QOL may shed some light on this subject. The available data suggest that QOL is considerably impaired in patients with AF compared with that of age-matched controls. Moreover, some studies show that restoration of sinus rhythm is associated with improved QOL and better exercise performance. 46, [51] [52] [53] [54] The effect of AF on QOL was assessed in a substudy of the Canadian Trial of Atrial Fibrillation (CTAF). 55 The original study was a multicenter, prospective, and randomized clinical trial of amiodarone compared with either propafenone or sotalol in patients with recent onset of AF. The results of the CTAF substudy indicated that QOL, measured by the most widely validated generic health scale available, was significantly lower among patients with AF compared with healthy controls. Because the patients were relatively young and healthy (most had normal left ventricular function, and there was a low incidence of comorbid illnesses such as ischemic heart disease or diabetes mellitus), this suggests that AF per se was responsible for QOL impairment. Furthermore, the majority of patients were receiving medications to control ventricular response at baseline. In addition to symptoms directly attributable to the arrhythmia itself, general wellbeing, physical and social function, and vitality were substantially impaired in patients with AF, who perceived themselves more often as having "heart disease." After restoration of sinus rhythm, there was substantial improvement, particularly in physical role functioning, vitality, social functioning, and symptoms frequency and severity. Although this improvement may have been the result of a drug effect or adjustment of other therapies (including rate-controlling agents), the improved QOL in patients who did not have any recurrence over patients with such a recurrence signifies the role of rhythm control in these patients.
New-onset AF is of particular pathophysiological, clinical, and prognostic importance and hence deserves special therapeutic considerations. New-onset AF is associated with a significantly higher risk for death compared with no AF or persistent AF. In a 21-year community-based cohort study of patients with newly diagnosed AF, the mortality risk was substantially higher within the first 4 months, with a hazard ratio of 9.62 (95% CI, 8.93 to 10.32) as compared with a hazard ratio of 1.66 (95% CI 1.59 to 1.73) thereafter. 3 Similarly, in an analysis of the Carvedilol Or Metoprolol European Trial (COMET), new-onset AF, but not baseline AF, was an independent predictor of all-cause mortality. 8 This observation was also confirmed in the Framingham Heart Study. 56 Few plausible mechanisms may explain why new onset of AF is associated with a worse outcome. First, as discussed above, the first appearance of AF set multiple pathophysiological mechanisms in motion, favoring remodeling of the left atria and thereby promoting the conversion of paroxysmal AF into persistent AF. Emerging data also demonstrate that acute-onset AF is associated with a prothrombotic state that includes activation of platelets, decreased endocardial nitric oxide synthase expression, and increased expression of plasminogen activator inhibitor 1. 57, 58 These events occur at a local cardiac level before manifesting in the peripheral circulation and are due to AF per se and not the rapid ventricular rate seen during the arrhythmia. Second, the adequacy of rate control, achieved either naturally over time or by medications, is usually better than ventricular rates accompanying a new presentation of AF. Third, the potential for treatment with harmful antiarrhythmic medications is highest at the beginning of AF. Lastly, initiation of warfarin therapy, especially in elderly patients, carries considerable risk for both under and over anticoagulation, despite adherence to well-established warfarin initiation protocols. 59 Although it is likely that progression to persistent AF also requires a substrate beyond a pure electrical burden, it seems reasonable to attempt early cardioversion in order to disrupt this vicious cycle. Many patients maintain sinus rhythm for prolonged periods after an initial cardioversion, even without antiarrhythmic treatment, especially if precipitating factors are identified and treated.
Catheter Ablation
AFFIRM demonstrated that the favorable influence of sinus rhythm may be counterbalanced by the harm caused by currently available AADs. 49 Radiofrequency catheter ablation is a new but widely adopted technique for the treatment of AF that provides an alternative approach for maintaining sinus rhythm. 60 -63 Several small randomized trials have consistently demonstrated the superiority of catheter ablation over antiarrhythmic therapy. 64 -67 Typically these trials have been much more stringent in the electrocardiographic detection of AF recurrence than has been the case with AAD trials. Stabile et al 66 randomized 137 patients with drug-refractory AF to ablation with AAD or AAD alone. At 1 year, freedom from AF was achieved in 65.9% of patients randomized to catheter ablation combined with AAD, as compared with 8.7% in patients receiving only AAD. Pappone et al 67 randomized 198 patients with long-standing paroxysmal AF who failed AAD therapy to either catheter ablation or maximal tolerable doses of another AAD. At 1 year, 93% and 35% of the catheter ablation and AAD groups, respectively, were free of atrial tachyarrhythmias. Wazni et al 65 randomized symptomatic patients who had not received prior treatment for AF (aged 18 to 75 years) to undergo either catheter ablation or receive AAD therapy. At 1-year follow-up, only 13% of the patients who underwent catheter ablation had recurrence of symptomatic AF as compared with 63% of those randomized to AAD. Catheter ablation was also associated with a significantly better QOL. In a recent meta-analysis of studies comparing catheter ablation with AAD therapy for AF, Noheria et al 68 showed that, in a selective group of methodologically qualified, prospective, and randomized studies, catheter ablation was associated with a 75.7% atrial tachyarrhythmias recurrence-free survival rate, as compared with 18.8% in the AAD therapy group (Figure 2 ). These trials should be considered as hypothesis-generating, and generalizing the results of ablation trials would be as potentially hazardous as generalizing the results of the AFFIRM trial has been. Duration of follow-up has been short, and patients enrolled have generally been young and relatively healthy. Hopefully, the results of more substantial trials (in terms of number of subjects, broader demographics, and longer follow-up), such as the Radiofrequency Ablation versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (RAAFT), 69 the Catheter Ablation for the Cure of Atrial Fibrillation (CACAF-2), 70 and the Catheter ABlation versus ANtiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) will clarify the role of catheter ablation in the disease management of AF. The proposed CABANA study plans to enroll 3000 subjects with a similar demographic as the AFFIRM study, who will be randomized to either catheter ablation or best drug therapy (which includes both rate control and rhythm control). The primary end point is mortality over 3 years, whereas secondary end points include stroke, serious bleeding, freedom from AF, symptoms, and QOL.
Conclusions
As the population continues to age, partially because of better therapies for atherosclerosis and heart failure, and becomes increasingly overweight, AF will not only become more prevalent, its effect on morbidity and mortality is likely to become even more important. We should therefore focus on therapies that improve prognosis rather than embracing remedies that are, at best, noninferior to current standard of care. Recent research has led to better understanding of basic mechanisms involved in the development and perpetuation of the arrhythmia. Although present merely as an electrical pathology, AF is a dynamic disease, with a well-characterized pattern of progression. Therapy for AF should be active rather than passive, particularly early in the disease process ( Figure  3 ). The underlying pathophysiology suggests that there is a window period where therapy may yield substantial benefit A new paradigm for treatment of AF, similar to the staged approach for treatment of heart failure. This figure expresses (1) the need for risk factor modification before disease expression, (2) the window period of opportunity for aggressive rhythm control therapy at early stages of the disease, and (3) the probable failure of aggressive attempts at rhythm control in advanced stages of the atrial remodeling process after irreversible remodeling is established. CAD indicates coronary artery disease; SR, sinus rhythm.
( Table) ; later in the process, when widespread atrial fibrosis has already occurred, aggressive therapy is no longer warranted. Treatment should start with prevention of the atrial remodeling and progressive fibrosis. This can be achieved by treating hypertension, sleep apnea, obesity, coronary disease, and heart failure. Once AF occurs, early restoration of sinus rhythm followed by maintenance rhythm control therapy is recommended, particularly in patients who can reasonably be expected to live longer than the 2 to 3 years of follow-up that current trials have provided. Combined with risk factor control, this strategy provides the highest chance for halting disease progression and, if successful and started early in the process, even reverse remodeling. Properly monitored AAD therapy may be useful in selected patients to maintain sinus rhythm after cardioversion. Although more research is clearly needed, catheter ablation appears to be safe and more effective than AADs, at least in highly selected patients (arguably the ones who have the most to gain) when performed at experienced centers. New therapies based on the first fruits of greater pathophysiological understanding of the AF disease process will undoubtedly be discovered and applied in the immediate future.
The frequently offered excuse that we have imperfect tools no longer, in our opinion, carries the day. We think that fighting the good fight with our currently available armamentarium may prevent a hopeless situation in the future when better therapies are available.
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